<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>2</IssueIDStart>
          <IssueIDEnd>2</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>6</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art9">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>72345</ArticleID>
            <ArticleDOI>10.1208/aapsj070234</ArticleDOI>
            <ArticleSequenceNumber>9</ArticleSequenceNumber>
            <ArticleTitle Language="En">Small-molecule agonists and antagonists of the opioid receptor-like receptor (ORL1, NOP): Ligand-based analysis of structural factors influencing intrinsic activity at NOP</ArticleTitle>
            <ArticleFirstPage>E345</ArticleFirstPage>
            <ArticleLastPage>E352</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>1</Month>
                <Day>19</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>2</Month>
                <Day>8</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>2</IssueIDStart>
              <IssueIDEnd>2</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Nurulain</GivenName>
                  <FamilyName>Zaveri</FamilyName>
                </AuthorName>
                <Role>Drug Discovery Program Director</Role>
                <Contact>
                  <Phone>650-859-6041</Phone>
                  <Fax>650-859-3153</Fax>
                  <Email>nurulain.zaveri@sri.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Faming</GivenName>
                  <FamilyName>Jiang</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Cris</GivenName>
                  <FamilyName>Olsen</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Willma</GivenName>
                  <FamilyName>Polgar</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Lawrence</GivenName>
                  <FamilyName>Toll</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Biosciences Division</OrgDivision>
                <OrgName>SRI International</OrgName>
                <OrgAddress>
                  <Street>333 Ravenswood Ave</Street>
                  <Postcode>94025</Postcode>
                  <City>Menlo Park</City>
                  <State>CA</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>The recently discovered fourth member of the opioid receptor family, the nociceptin receptor (NOP) and its endogenous ligand, the heptadecaptide nociceptin, are involved in several central nervous system pathways, such as nociception, reward, tolerance, and feeding. The discovery of small-molecule ligands for NOP is being actively pursued for several therapeutic applications. This review presents a brief overview of the several recently reported NOP ligands, classified as NOP agonists and antagonists, with an emphasis on the analysis of the structural features that may be important for modulating the agonist/antagonist profile (intrinsic activity) of these ligands. Structure-activity relationships in our own series of dihydroindolinone-based NOP ligands and those of the various reported ligands indicate that the lipophilic substituent on the common basic nitrogen present in all NOP ligands plays a role in determining the agonist/antagonist profile of the NOP ligand. This analysis provides a basis for the rational drug design of NOP ligands of desired intrinsic activity and provides a framework for developing pharmacophore models for high affinity binding and intrinsic activity at the NOP receptor. Since NOP agonists and antagonists both have therapeutic value, rational approaches for obtaining both within a high-affinity binding class of compounds are very useful for designing potent and selective NOP ligands with the desired profile of intrinsic efficacy.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>nociceptin</Keyword>
              <Keyword>opioid receptor-like</Keyword>
              <Keyword>ORL1</Keyword>
              <Keyword>NOP</Keyword>
              <Keyword>agonist</Keyword>
              <Keyword>antagonist</Keyword>
              <Keyword>intrinsic activity</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: October 5, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_72345.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Bigoni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Giuliani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Calo'</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies</ArticleTitle>
                  <JournalTitle>Naunyn Schmiedebergs Arch Pharmacol.</JournalTitle>
                  <VolumeID>359</VolumeID>
                  <FirstPage>160</FirstPage>
                  <LastPage>167</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10208302</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/PL00005338</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXhtlKmsbY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bigoni R, Giuliani S, Calo' G, et al. Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies.<Emphasis Type="Italic">Naunyn Schmiedebergs Arch Pharmacol.</Emphasis> 1999;359:160–167.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Mollereau</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Mouledous</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Tissue distribution of the opioid receptor-like (ORL1) receptor</ArticleTitle>
                  <JournalTitle>Peptides</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>907</FirstPage>
                  <LastPage>917</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10998524</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0196-9781(00)00227-8</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXms1WrsLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mollereau C, Mouledous L. Tissue distribution of the opioid receptor-like (ORL1) receptor.<Emphasis Type="Italic">Peptides</Emphasis>. 2000;21:907–917.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Mogil</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GW</Initials>
                    <FamilyName>Pasternak</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family</ArticleTitle>
                  <JournalTitle>Pharmacol Rev.</JournalTitle>
                  <VolumeID>53</VolumeID>
                  <FirstPage>381</FirstPage>
                  <LastPage>415</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11546835</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXntlels7s%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family.<Emphasis Type="Italic">Pharmacol Rev.</Emphasis> 2001;53:381–415.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Calo'</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>R</Initials>
                    <FamilyName>Guerrini</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Rizzi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Salvadori</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Regoli</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Pharmacology of noniceptin and its receptor: a novel therapeutic target</ArticleTitle>
                  <JournalTitle>Br J Pharmacol.</JournalTitle>
                  <VolumeID>129</VolumeID>
                  <FirstPage>1261</FirstPage>
                  <LastPage>1283</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10742280</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.bjp.0703219</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Calo' G, Guerrini R, Rizzi A, Salvadori S, Regoli D. Pharmacology of noniceptin and its receptor: a novel therapeutic target.<Emphasis Type="Italic">Br J Pharmacol.</Emphasis> 2000;129:1261–1283.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Zaveri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WE</Initials>
                    <FamilyName>Polgar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CM</Initials>
                    <FamilyName>Olsen</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors</ArticleTitle>
                  <JournalTitle>Eur J Pharmacol.</JournalTitle>
                  <VolumeID>428</VolumeID>
                  <FirstPage>29</FirstPage>
                  <LastPage>36</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11779034</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0014-2999(01)01282-1</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXnsVSlur8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zaveri N, Polgar WE, Olsen CM, et al. Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors.<Emphasis Type="Italic">Eur J Pharmacol.</Emphasis> 2001;428:29–36.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Lutfy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Eitan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Bryant</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors</ArticleTitle>
                  <JournalTitle>J Neurosci.</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <FirstPage>10331</FirstPage>
                  <LastPage>10337</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14614092</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXpt1ylurY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lutfy K, Eitan S, Bryant C, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.<Emphasis Type="Italic">J Neurosci.</Emphasis> 2003;23: 10331–10337.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>N</Initials>
                    <FamilyName>Zaveri</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents</ArticleTitle>
                  <JournalTitle>Life Sci.</JournalTitle>
                  <VolumeID>73</VolumeID>
                  <FirstPage>663</FirstPage>
                  <LastPage>678</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12801588</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0024-3205(03)00387-4</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXksVeht7c%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zaveri N. Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents.<Emphasis Type="Italic">Life Sci.</Emphasis> 2003;73:663–678.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Ronzoni</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Peretto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GA</Initials>
                    <FamilyName>Giardina</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Lead generation and lead optimization approaches in the discovery of selective, nonpeptide ORL-1 receptor agonists and antagonists</ArticleTitle>
                  <JournalTitle>Expert Opin Ther Patents</JournalTitle>
                  <VolumeID>11</VolumeID>
                  <FirstPage>525</FirstPage>
                  <LastPage>546</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1517/13543776.11.4.525</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXis1emu7c%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ronzoni S, Peretto I, Giardina GA. Lead generation and lead optimization approaches in the discovery of selective, nonpeptide ORL-1 receptor agonists and antagonists.<Emphasis Type="Italic">Expert Opin Ther Patents</Emphasis>. 2001;11:525–546.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NT</Initials>
                    <FamilyName>Zaveri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Jiang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CM</Initials>
                    <FamilyName>Olsen</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor</ArticleTitle>
                  <JournalTitle>J Med Chem.</JournalTitle>
                  <VolumeID>47</VolumeID>
                  <FirstPage>2973</FirstPage>
                  <LastPage>2976</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15163178</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm034249d</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXjs1Sjs7s%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zaveri NT, Jiang F, Olsen CM, et al. A novel series of piperidin-4-yl-1,3-dihydroindol-2-ones as agonist and antagonist ligands at the nociceptin receptor.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2004;47:2973–2976.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Wichmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Adam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rover</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one, a potent and selective orphanin FO (OFQ) receptor agonist with anxiolytic-like properties</ArticleTitle>
                  <JournalTitle>Eur J Med Chem.</JournalTitle>
                  <VolumeID>35</VolumeID>
                  <FirstPage>839</FirstPage>
                  <LastPage>851</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11006485</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0223-5234(00)00171-9</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXmvFKhtLY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Wichmann J, Adam G, Rover S, et al. Synthesis of (1S,3aS)-8-(2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triazaspiro[4,5]decan-4-one, a potent and selective orphanin FO (OFQ) receptor agonist with anxiolytic-like properties.<Emphasis Type="Italic">Eur J Med Chem.</Emphasis> 2000;35:839–851.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rover</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Adam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Cesura</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor</ArticleTitle>
                  <JournalTitle>J Med Chem.</JournalTitle>
                  <VolumeID>43</VolumeID>
                  <FirstPage>1329</FirstPage>
                  <LastPage>1338</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10753470</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm991129q</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD38%2FgsFGmsQ%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rover S, Adam G, Cesura AM, et al. High-affinity, non-peptide agonists for the ORL1 (orphanin FQ/nociceptin) receptor.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2000;43:1329–1338.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Rover</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Wichmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Jenck</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Adam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Cesura</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">ORL1 receptor ligands: structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones</ArticleTitle>
                  <JournalTitle>Bioorg Med Chem Lett.</JournalTitle>
                  <VolumeID>10</VolumeID>
                  <FirstPage>831</FirstPage>
                  <LastPage>834</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10782696</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0960-894X(00)00111-6</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXis12isbg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rover S, Wichmann J, Jenck F, Adam G, Cesura AM. ORL1 receptor ligands: structure-activity relationships of 8-cycloalkyl-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-ones.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 2000;10:831–834.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibUnstructured>Ito F, Ohashi Y, inventor. Pfizer, Inc., assignee. 1,3,8-Triazaspiro[4,5]decanone compounds as ORL1-receptor agonists. European patent application, European patent 0 997 464 A1. July 10, 1999.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Kolczewski</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Adam</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AM</Initials>
                    <FamilyName>Cesura</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Novel hexahydrospiro [piperidine-4,1′[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptors agonists</ArticleTitle>
                  <JournalTitle>J Med Chem.</JournalTitle>
                  <VolumeID>46</VolumeID>
                  <FirstPage>255</FirstPage>
                  <LastPage>264</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12519064</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm0209174</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XpsVegtLs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kolczewski S, Adam G, Cesura AM, et al. Novel hexahydrospiro [piperidine-4,1′[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptors agonists.<Emphasis Type="Italic">J Med Chem.</Emphasis> 2003;46:255–264.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibUnstructured>Tulshian D, Ho GD, Silverman LS, et al, inventor. Schering Corporation, assignee. High affinity ligands for nociceptin receptor ORL-1. US patent 6 262 066 B1. July 17, 2001.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>Z</Initials>
                    <FamilyName>Chen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>WS</Initials>
                    <FamilyName>Miller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Shan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>KJ</Initials>
                    <FamilyName>Valenzano</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor</ArticleTitle>
                  <JournalTitle>Bioorg Med Chem Lett.</JournalTitle>
                  <VolumeID>13</VolumeID>
                  <FirstPage>3247</FirstPage>
                  <LastPage>3252</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12951102</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0960-894X(03)00665-6</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXmvV2lt74%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Chen Z, Miller WS, Shan S, Valenzano KJ. Design and parallel synthesis of piperidine libraries targeting the nociceptin (N/OFQ) receptor.<Emphasis Type="Italic">Bioorg Med Chem Lett.</Emphasis> 2003;13:3247–3252.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Kawamoto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Ozaki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Itoh</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Discovery of the first potent and selective small molecular opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397)</ArticleTitle>
                  <JournalTitle>J Med Chem.</JournalTitle>
                  <VolumeID>42</VolumeID>
                  <FirstPage>5061</FirstPage>
                  <LastPage>5063</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10602690</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm990517p</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXnsFOmt7o%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kawamoto H, Ozaki S, Itoh Y, et al. Discovery of the first potent and selective small molecular opioid receptor-like (ORL1) antagonist: 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1, 3-dihydro-2H-benzimidazol-2-one (J-113397).<Emphasis Type="Italic">J Med Chem.</Emphasis> 1999;42:5061–5063.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibUnstructured>Ozaki S, Kawamoto H, Ito Y, Hayashi K, Hirano K, Iwasawa Y, inventor. Banyu Pharmaceutical Co., assignee. New 2-oxoimidazole derivatives. US patent 6 258 825. July 10, 2001.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibUnstructured>Kawamoto H, Ozaki S, Ito, Y, Iwazawa Z, inventor. Banyu Pharmaceutical Co, assignee. 4-Oxoimidazolidine-5-spiro-nitrogen-containing heterocyclic compound. Japan patent application 20001169476. June 20, 2000.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PF</Initials>
                    <FamilyName>Zaratin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Petrone</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Sbacchi</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Modification of nociceptin and morphine tolerance by the selective ORL-1 antagonist (−)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther.</JournalTitle>
                  <VolumeID>308</VolumeID>
                  <FirstPage>454</FirstPage>
                  <LastPage>461</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14593080</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.103.055848</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhtlSqtLo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Zaratin PF, Petrone G, Sbacchi M, et al. Modification of nociceptin and morphine tolerance by the selective ORL-1 antagonist (−)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111).<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> 2004;308:454–461.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Shinkai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Ito</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Iida</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Kitao</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Yamada</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Uchida</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">4-Aminoquinolines: novel nociceptin antagonists with analgesic activity</ArticleTitle>
                  <JournalTitle>J med Chem.</JournalTitle>
                  <VolumeID>43</VolumeID>
                  <FirstPage>4667</FirstPage>
                  <LastPage>4677</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11101358</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1021/jm0002073</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXnvVKhsb0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shinkai H, Ito T, Iida T, Kitao Y, Yamada H, Uchida I. 4-Aminoquinolines: novel nociceptin antagonists with analgesic activity.<Emphasis Type="Italic">J med Chem.</Emphasis> 2000;43:4667–4677.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Yamada</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Nakamoto</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>Y</Initials>
                    <FamilyName>Suzuki</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Ito</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Aisaka</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Pharmacological profiles of a novel opioid receptor-likel (ORL1) receptor antagonist, JTC-801</ArticleTitle>
                  <JournalTitle>Br J Pharmacol.</JournalTitle>
                  <VolumeID>135</VolumeID>
                  <FirstPage>323</FirstPage>
                  <LastPage>332</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11815367</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1038/sj.bjp.0704478</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xht1KrsLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Yamada H, Nakamoto H, Suzuki Y, Ito T, Aisaka K. Pharmacological profiles of a novel opioid receptor-likel (ORL1) receptor antagonist, JTC-801.<Emphasis Type="Italic">Br J Pharmacol.</Emphasis> 2002;135:323–332.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibUnstructured>Muratani T, Minami T, Enomoto U, et al. Characterization of nociceptin/orphanin FQ-induced pain responses by the novel receptor antagonist N-(4-amino-2-methylquinolin-6-yl)-2-(4-ethylphenoxymethyl) benzamide monohydrochloride. In:<Emphasis Type="Italic">J Pharmacol Exp Ther.</Emphasis> vol. 303. 2002:424–430.</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Mabuchi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Matsumura</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Okuda-Ashitaka</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production</ArticleTitle>
                  <JournalTitle>Eur J Neurosci.</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>1384</FirstPage>
                  <LastPage>1392</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12713641</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1046/j.1460-9568.2003.02575.x</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mabuchi T, Matsumura S, Okuda-Ashitaka E, et al. Attenuation of neuropathic pain by the nociceptin/orphanin FQ antagonist JTC-801 is mediated by inhibition of nitric oxide production.<Emphasis Type="Italic">Eur J Neurosci.</Emphasis> 2003;17:1384–1392.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Mouledous</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CM</Initials>
                    <FamilyName>Topham</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Moisand</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>C</Initials>
                    <FamilyName>Mollereau</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JC</Initials>
                    <FamilyName>Meunier</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain</ArticleTitle>
                  <JournalTitle>Mol Pharmacol.</JournalTitle>
                  <VolumeID>57</VolumeID>
                  <FirstPage>495</FirstPage>
                  <LastPage>502</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10692489</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXhvFaisbc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Mouledous L, Topham CM, Moisand C, Mollereau C, Meunier JC. Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain.<Emphasis Type="Italic">Mol Pharmacol.</Emphasis> 2000,57:495–502.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
